人兽共患戊型肝炎与口蹄疫联合疫苗的设计及免疫原性分析
研究通过分子克隆技术制备并纯化9种戊型肝炎病毒(HEV)4型ORF2截短蛋白,筛选出p222蛋白可自组装为约34nm病毒样颗粒(VLP)且稳定性与抗原性/免疫原性优于其他HEV抗原。以Montanide ISA-206为佐剂制备HEV单苗、口蹄疫病毒(FMDV)单苗及HEV-FMDV联合疫苗免疫小鼠,监测12周体液免疫应答。结果显示联合疫苗诱导的抗FMDV抗体滴度较FMDV单苗高7-16倍,抗HEV抗体滴度较HEV p222单抗原高2.4倍,提示对两种抗原免疫原性有协同效应。
要点
- HEV p222蛋白可自组装为约34nm VLP,稳定性和抗原性/免疫原性优于其他HEV抗原。
- HEV-FMDV联合疫苗诱导的抗FMDV抗体滴度较FMDV单苗高7-16倍。
- 联合疫苗诱导的抗HEV抗体滴度较HEV p222单抗原高2.4倍,提示协同效应。
核心结论
- 作者提出通过控制主要宿主(猪)来控制人兽共患HEV感染的新途径,并设计了首个HEV-FMDV联合疫苗,初步分析显示对HEV和FMDV两种抗原的免疫原性具有协同效应。
研究设计与样本
- 采用分子克隆技术制备并纯化9种HEV基因4型ORF2截短蛋白,比较热稳定性、抗原性和免疫原性以筛选最佳HEV免疫原。
- 以Montanide ISA-206为佐剂制备HEV单苗、FMDV单苗和HEV-FMDV联合疫苗不同配方,免疫小鼠并监测至免疫后12周的体液免疫应答。
主要发现
- HEV p222蛋白可自组装为约34nm的VLP,与其他HEV抗原相比显示出更高的稳定性和更好的抗原性/免疫原性,被选为最佳HEV免疫原。
- FMDV单苗免疫小鼠诱导高滴度FMDV特异性抗体,呈剂量依赖性;HEV p222蛋白也诱导高水平抗HEV抗体,但呈非剂量依赖性。
- HEV-FMDV联合疫苗诱导的抗FMDV抗体滴度较FMDV单苗诱导的滴度高7-16倍,抗HEV抗体滴度较HEV p222单抗原诱导的滴度高2.4倍。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Design and immunogenicity assessment of the combined vaccine candidate against zoonotic hepatitis E virus (HEV) and foot-and-mouth disease virus (FMDV). METHODS: Using the molecular cloning technology, we produced and purified 9 HEV ORF2-truncated proteins (HEV genotype 4). Then, we compared their thermal stability, antigenicity, and immunogenicity to select the best HEV immunogen. Next, we used the adjuvant Montanide ISA-206 to prepare different formulations of HEV vaccine alone, FMDV vaccine alone and HEV-FMDV combined vaccine. The formulations were injected into mice and the induced humoral immune responses were monitored up 12 weeks post-immunization. RESULTS: The HEV p222 protein could self-assemble into VLPs (∼34 nm) and showed higher stability and better antigenicity/immunogenicity than the other HEV antigens, thus it was selected as the best HEV immunogen. Mice immunization with the FMDV vaccine alone induced high FMDV-specific antibody titers in a dose-dependent manner; the HEV p222 protein also induced high levels of anti-HEV antibodies but in a dose-independent manner. The HEV-FMDV combination induced anti-FMDV antibody titers 7-16-fold higher than the titers induced by the FMDV vaccine alone, and HEV-specific antibody titers 2.4-fold higher than those induced by the HEV p222 antigen alone. CONCLUSION: Herein, we proposed a new approach for the control of zoonotic HEV infection through its control in its main host (pig). We also designed the first HEV-FMDV combined vaccine and the preliminary analyses revealed a synergistic effect on the immunogenicity of both HEV and FMDV antigens.
引用
- Liu Z, Behloul N, Baha S, et al. Design and immunogenicity analysis of the combined vaccine against zoonotic hepatitis E and foot-and-mouth disease. Vaccine. 2019. PMID: 31604580. doi:10.1016/j.vaccine.2019.09.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。